COMPARATIVE EFFICACY OF 200 UNITS VERSUS 155 UNITS OF ONABOTULINUMTOXIN A FOR CHRONIC MIGRAINE.

This study looked at how effective different doses of onabotulinumtoxin A (OnaBT-A) are for treating chronic migraine. Chronic migraine affects many people and can be hard to manage. Researchers conducted this study in Mosul, Iraq, with 106 patients diagnosed with chronic migraine. They divided the patients into two groups. One group received 200 units of OnaBT-A, while the other group received 155 units. Both groups received the injections at the beginning of the trial and again after 12 weeks. The researchers measured various factors, including headache frequency, severity, duration, and disability. The results showed that both doses improved these headache symptoms significantly. This suggests that OnaBT-A is effective in treating chronic migraine, and the dose may influence the level of improvement experienced by patients. Clinical relevance: This research indicates that higher doses of OnaBT-A may lead to better outcomes for chronic migraine patients, potentially guiding treatment decisions for clinicians.